Moderna’s personalized mRNA melanoma therapy intismeran took a major step forward as the company’s Phase 3 study met its primary goal, supporting improved outcomes in patients with melanoma. The result, presented at the European Society for Medical Oncology meeting in Madrid, builds on a decade of work and a partnership with Merck that helped advance clinical development. Moderna CEO Stéphane Bancel said most in the field doubted the vaccine approach, but the Phase 3 readout reflects that the program reached its intended clinical validation point. Beyond the clinical impact, the company framed the success as a pivot for its broader R&D strategy—signaling that individualized mRNA designs can deliver measurable benefit and shape how Moderna prioritizes pipeline bets after a long development cycle.